It accused its American and German competitors of “copying” mRNA technology without its permission.
Moderna faces Pfizer in the British courts
Yassin Ahmed (London) @OKAZ_online
Yassin Ahmed (London) @OKAZ_online
Every coffee keeps the site running. Thank you!
Tech, gaming and the news that matters
It accused its American and German competitors of “copying” mRNA technology without its permission.
Moderna faces Pfizer in the British courts
Yassin Ahmed (London) @OKAZ_online
Yassin Ahmed (London) @OKAZ_online
High manufacturing costs and complex delivery logistics force biopharma firms to rethink commercialization strategies.
Not a stimulant in the way most people think. It blocks tiredness rather than adding energy.
Biotechnology firms are reporting accelerated candidate identification, though clinical trial safety milestones remain unchanged.
Widespread demand for metabolic treatments forces drugmakers to outsource secondary packaging and fill-finish capacity.
Broad adoption of GLP-1 weight-loss drugs is compelling health insurers to re-evaluate long-term chronic care cost projections.
Pharmaceutical developers are expanding clinical pipelines for specialized RNA therapeutics targeting previously untreatable genetic mutations.